Egypt vs Landlocked developing countries (LLDCs): Percentage of bloodstream infection due to methicillin-resistant
Egypt
69.4%
in 2022
Landlocked developing countries (LLDCs)
53.8%
in 2022
Egypt rank
2nd
Landlocked developing countries (LLDCs) rank
3rd
Percentage of bloodstream infection due to methicillin-resistant over time
- Egypt
- Landlocked developing countries (LLDCs)
How they compare
Egypt currently reports 69.4% against 53.8% in Landlocked developing countries (LLDCs), a difference of 15.6%.
That makes Egypt's figure about 1.3 times Landlocked developing countries (LLDCs)'s.
Across all 5 years both countries report, Egypt has been ahead every year.
Egypt ranks 2nd and Landlocked developing countries (LLDCs) ranks 3rd of 44 countries.
Egypt has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Egypt | Landlocked developing countries (LLDCs) | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 75.0% | 21.0% | 54.0% | Egypt |
| 2020s | 87.3% | 62.2% | 25.0% | Egypt |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher percentage of bloodstream infection due to methicillin-resistant, Egypt or Landlocked developing countries (LLDCs)?
- Egypt, at 69.4% against 53.8% in Landlocked developing countries (LLDCs) as of 2022.
- What is the difference in percentage of bloodstream infection due to methicillin-resistant between Egypt and Landlocked developing countries (LLDCs)?
- 15.6%, with Egypt ahead.
- How many years of comparable data are there for Egypt and Landlocked developing countries (LLDCs)?
- 5 years are reported by both, from 2018 to 2022.
- How do Egypt and Landlocked developing countries (LLDCs) rank globally for percentage of bloodstream infection due to methicillin-resistant?
- Egypt ranks 2nd and Landlocked developing countries (LLDCs) ranks 3rd of 44 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.